Cyclacel Pharmaceuticals, Inc.·4

Feb 2, 4:18 PM ET

Rombotis Spiro George 4

4 · Cyclacel Pharmaceuticals, Inc. · Filed Feb 2, 2023

Insider Transaction Report

Form 4
Period: 2023-01-31
Rombotis Spiro George
DirectorPresident & C.E.O.
Transactions
  • Award

    Common Stock

    2023-01-31+57,60062,588 total
Footnotes (2)
  • [F1]The reporting person received an award of 57,600 restricted stock units on January 31, 2023, which shall vest in full on January 31, 2026, provided, however, that if certain clinical milestones are achieved then such restricted stock units shall vest in full earlier in connection with such achievement.
  • [F2]Includes 4,988 shares of common stock and 57,600 restricted stock units.

Documents

1 file
  • 4
    tm235262-2_4seq1.xmlPrimary

    OWNERSHIP DOCUMENT